Form 4: enGene Holdings Grants Options to Chief Strategy Officer

enGene Holdings Inc. granted 195,000 stock options to Chief Strategy & Operations Officer Alexander Julian Nichols.

Summary

• Alexander Julian Nichols, Chief Strategy & Operations Officer of enGene Holdings Inc. (ENGN), was granted 195,000 stock options.
• The options have an exercise price of $9.53 per share.
• The transaction date for this grant was January 30, 2026.
• The options vest monthly in substantially equal amounts over 48 months, contingent on Mr. Nichols' continued service.
• The expiration date for these stock options is January 30, 2036.
• Following this transaction, Mr. Nichols beneficially owns 195,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies a standard executive compensation practice that aligns management's interests with shareholder value. It is not a direct indicator of financial performance but rather a governance and incentive mechanism.

Positives

• The grant of stock options aligns the Chief Strategy & Operations Officer's financial interests with those of shareholders, incentivizing long-term performance and value creation.
• The 48-month vesting schedule promotes executive retention and sustained focus on the company's strategic objectives.

Negatives

• No immediate negatives are apparent from this Form 4 filing, which primarily reports an executive compensation event.

Risks

• The value of the stock options is subject to the future market price of enGene Holdings Inc. common shares, which may fluctuate.
• The options' vesting is contingent on the reporting person's continued service, meaning unvested options could be forfeited if employment ceases.
• Dilution risk to existing shareholders if all options are exercised, although this is a standard aspect of equity compensation plans.

Future Outlook

The 48-month vesting schedule for the stock options indicates a long-term incentive structure designed to retain the Chief Strategy & Operations Officer and align their performance with the company's strategic goals over the next four years.

Industry Context

StockSavvy.ai notes that stock option grants are a common form of executive compensation in the biotechnology and pharmaceutical industries. This practice is widely adopted to attract, retain, and motivate key executives by linking their financial success directly to the company's long-term share price performance and strategic achievements.

Comparison to Industry Standards

• StockSavvy.ai observes that a 4-year vesting schedule, as seen in this grant, is a common industry standard for executive equity grants. This aligns with practices at comparable biotech firms, such as those observed in executive compensation packages at companies like Moderna or BioNTech, which often utilize multi-year vesting to ensure long-term retention and performance alignment.
• The exercise price of $9.53, likely the market price on the grant date, is typical for at-the-money option grants, a standard practice in executive compensation plans across the sector.

Related Party Transactions

• This filing reports an executive compensation transaction involving a Chief Strategy & Operations Officer, which is an insider transaction.

Stakeholder Impact

• Shareholders: Potential for increased alignment of executive incentives with long-term shareholder value creation.
• Employees (specifically the reporting person): Receipt of equity compensation as part of their overall remuneration package, providing a direct stake in the company's future success.

Next Steps

• Continued service by Alexander Julian Nichols is required for the monthly vesting of the stock options over the next 48 months.

Key Dates

Keywords

enGene Holdings, ENGN, Stock Options, Executive Compensation, Form 4, Insider Transaction, Alexander Nichols, Equity Grant